ERRATUM

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

Kara N. Maxwell¹ · Danielle Soucier-Ernst² · Emin Tahirovic³ · Andrea B. Troxel⁷ · Candace Clark² · Michael Feldman⁴ · Christopher Colameco² · Bijal Kakrecha¹ · Melissa Langer⁸ · David Lieberman⁴ · Jennifer J. D. Morrisette⁴ · Matt R. Paul⁵ · Tien-chi Pan⁵ · Stephanie Yee¹ · Natalie Shih⁴ · Erica Carpenter^{1,2} · Lewis A. Chodosh^{2,5,6} · Angela DeMichele^{1,2,3}

Published online: 26 June 2017
© Springer Science+Business Media, LLC 2017

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-017-4257-x

In the original publication of the article, the labelling for the legend of Fig. 3a was erroneously switched. The corrected Fig. 3 is given in this erratum.

The online version of the original article can be found under doi:[10.1007/s10549-017-4257-x](https://doi.org/10.1007/s10549-017-4257-x).

✉ Angela DeMichele
angela.demichele@uphs.upenn.edu

¹ Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

² Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

³ Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

⁴ Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

⁵ Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

⁶ Department of Medicine, Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

⁷ Department of Population Health, NYU School of Medicine, New York, NY, USA

⁸ University of Maryland School of Medicine, Baltimore, MD, USA

Fig. 3 Analysis of time to progression on standard treatment stratified by genomic biomarkers. **a** Patients were stratified into a high mutational load or low mutational load group. Time from initiation of treatment to first progression was analyzed using a Cox proportional-hazard model and adjusting for receptor status of the metastatic biopsy, number of lines of therapy and hormonal treatment versus chemotherapy. **b** Patients were stratified into a *TP53* mutation positive or *TP53* mutation negative group. Time from initiation of treatment to first progression was analyzed using a Cox proportional-hazard model and adjusting for receptor status of the metastatic biopsy, number of lines of therapy, and hormonal treatment versus chemotherapy